×

Novo Nordisk A/S : Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba(r) and Ryzodeg(r) in the US

BAGSVAERD, Denmark, March 26, 2015 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.

For further information

Media:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company Announcement No 23 / 2015

Company Announcement No 23 2015 http://hugin.info/2013/R/1906649/678864.pdf

HUG#1906649

Source:Novo Nordisk A/S